Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether plasma exchange as well as
immunosuppressive therapy are effective in reducing death and end-stage renal disease (ESRD).
The trial will also study whether a reduced cumulative dosing regimen of glucocorticoids is
as effective as a standard disease regimen.
The FDA-OOPD is one of the funding sources for this study.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Cambridge University Hospitals NHS Foundation Trust National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) University of Birmingham